bs-20067R-BF405 [Conjugated Primary Antibody]
C-jun Polyclonal Antibody, AbBy Fluor® 405 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: C-jun

Immunogen Range: 231-331/331


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 3725

Swiss Prot: P05412

Source: KLH conjugated synthetic peptide derived from human C-jun

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

The human protooncogene JUN is the putative transforming gene of avian sarcoma virus 17, and it encodes a protein which is highly homologous to the viral protein. cJun (previously known as the Fos binding protein p39) and c Fos form a complex in the nucleus. AP 1 (activating protein 1) is a collective term referring to these dimeric transcription factors composed of Jun, Fos or ATF subunits that bind to a common DNA site, the AP1 binding site. AP 1 proteins, mostly the Jun group, regulate the expression and function of cell cycle regulators such as Cyclin D1, p53, p21 (cip1/waf1), p19 (ARF) and p16. Fos and Jun proto oncogene expression is induced transiently by a variety of extracellular stimuli associated with mitogenesis, differentiation processes or depolarization of neurons. JUN has been mapped to 1p32 to p31, a chromosomal region involved in both translocations and deletions in human malignancies.

Conjugation: AbBy Fluor® 405

Excitation/ Emission: 401nm/421nm

Size: 100ul

Concentration: 1ug/ul

Applications: FCM(1:20-100)

Predicted Molecular Weight: 43


Cross Reactive Species: Human

Predicted Cross Reactive Species: Mouse
Rat
Dog
Cow
Pig
Chicken

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Ling Junjun. et al. Exploration of Potential Targets and Mechanisms of Fisetin in the Treatment of Non-Small-Cell Lung Carcinoma via Network Pharmacology and In Vitro Validation. EVID-BASED COMPL ALT. 2022;2022:2383527Read more>>
VALIDATION IMAGES